TIP Regimen Combined With Toripalimab Neoadjuvant Therapy for Locally Advanced Penile Cancer

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 6 more changesShow less
    • Primary completion date changed from estimate of Jun 1, 2027 to Aug 30, 2026
    • Interventions: Paclitaxel + Ifosfamide + Cisplatin & Toripalimab (Drug) to Paclitaxel + Ifosfamide + Cisplatin & Toripalimab (Drug)
    • Study description revised
    • Site details revised
    • Study title revised
    • Eligibility criteria expanded, about 3 words
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 1, 2024 to May 31, 2024
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Primary Objective: To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with Toripalimab as a neoadjuvant treatment in locally advanced penile cancer
Trial Details
NCT Number NCT06415318
Lead Sponsor Sun Yat-sen University
Conditions
(from sponsor)		 Penile Cancer
Related terms Penile Neoplasms
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov